english.prescrire.org > Spotlight > Archives : 2015 > In the September issue of Prescrire International: Aflibercept (Eylea°) and diabetic macular oedema

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2015 : 1 | 30 | 60

In the September issue of Prescrire International:
Aflibercept (Eylea°) and diabetic macular oedema

FREE DOWNLOADAflibercept (Eylea°), a VEGF inhibitor, is authorised for intravitreal administration in the treatment of diabetic macular oedema. How does it compare to other VEGF inhibitors in this setting?
Full text available for free download.

Summary

  • Diabetic retinopathy is sometimes associated with focal or diffuse macular oedema, leading to severe loss of visual acuity. Few treatments are effective.
     
  • Aflibercept has similar efficacy to other VEGF inhibitors administered by intravitreal injection. Its adverse effect profile is also similar.
     
  • However, a publicly funded trial showed that aflibercept was more effective than its competitors in patients with marked visual loss, making it the drug of choice in this setting.

Full text available for free download.

 ©Prescrire 1 September 2015

"Aflibercept (Eylea°) and diabetic macular oedema" Prescrire Int 2015; 24 (163): 207. (Pdf, free)

Download the full review
Pdf, free